Editorial

ACURATE neo2: jack of all trades or master of none?

EuroIntervention 2023;19:18-19. DOI: 10.4244/EIJ-E-23-00012

Jan-Malte Sinning
Jan-Malte Sinning1, MD, PhD, FESC
1. Department of Cardiology, St. Vincent Hospital Cologne, Cologne, Germany
Transcatheter aortic valve implantation (TAVI) is now indicated across all risk categories of patients with symptomatic severe aortic stenosis and has been proposed as a first-line option for the majority of patients ≥75 years old. The former discussion of whether a patient should undergo surgical aortic valve replacement (SAVR) or TAVI is shifting from patient age and surgical risk to life expectancy and the associated lifetime management of aortic stenosis for an individual patient1.

As indications for TAVI expand to include younger and healthier patients who are expected to outlive their initial transcatheter heart valve (THV), understanding ...

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Continuously renewing and at the cutting edge: Welcome to EuroPCR 2023!

Latest news